Ritesh Mishra (@riteshkumarmis3) 's Twitter Profile
Ritesh Mishra

@riteshkumarmis3

MBBS @AIIMSBhubaneswr
MD Medicine @aiims_nd
DM Rheumatology trainee @Officialjipmer

ID: 592869526

calendar_today28-05-2012 16:32:45

1,1K Tweet

115 Takipçi

222 Takip Edilen

debaditya_roy (@debaditya_roy) 's Twitter Profile Photo

🔥2023 #ACR/AAHKS Guideline ⏱️Optimal Timing of Elective Total Hip/Knee #Arthroplasty 🦴#Osteoarthritis #Osteonecrosis ⏳AVOID DELAY! ⚡️Shared decision making remains cornerstone🤝 ⚡️Delay IF : 🚬Smoking 🧁Uncontrolled DM ⚡️Obesity NOT a C/I ⚡️Dont Defer due to Deformity!

🔥2023 #ACR/AAHKS Guideline

⏱️Optimal Timing of Elective Total Hip/Knee #Arthroplasty 🦴#Osteoarthritis #Osteonecrosis

⏳AVOID DELAY!

⚡️Shared decision making remains cornerstone🤝

⚡️Delay IF :

🚬Smoking
🧁Uncontrolled DM

⚡️Obesity NOT a C/I

⚡️Dont Defer due to Deformity!
Alberto Giraldo (@alb_giraldo) 's Twitter Profile Photo

Prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) 🔹Meta-analysis of 56 studies including 11,851 RA-ILD patients. 🔹The pooled prevalence of RA-ILD in this study was approximately 18.7%. 🔹13 risk factors for RA-ILD were

Prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease (RA-ILD)
🔹Meta-analysis of 56 studies including 11,851 RA-ILD patients.
🔹The pooled prevalence of RA-ILD in this study was approximately 18.7%. 
🔹13 risk factors for RA-ILD were
Autoinmunes Medicina Interna Parc Taulí (@autoinmi_tauli) 's Twitter Profile Photo

Nature: An update on autoantibodies in the idiopathic inflammatory myopathies ⏩Autoantibodies correlate with specific clinical phenotypes, aiding in the classification, diagnosis and prognostic assessment of these diseases. nature.com/articles/s4158…

Nature: An update on autoantibodies in the idiopathic inflammatory myopathies

⏩Autoantibodies correlate with specific clinical phenotypes, aiding in the classification, diagnosis and prognostic assessment of these diseases.

nature.com/articles/s4158…
Ritasman  Baisya (@ritasmanb) 's Twitter Profile Photo

👉Scleroderma mimicker 💥Scleredema 👉Proximal extremity, neck ,upper 🔙 🌟Doughy induration ✅Post infection, diabetes ✅No systemic symptom #ACR2024 #ACRAmbassador

👉Scleroderma mimicker 
💥Scleredema 
👉Proximal extremity, neck ,upper 🔙 
🌟Doughy induration 
✅Post infection, diabetes
✅No systemic symptom #ACR2024 #ACRAmbassador
Deepti Agarwal (@deepti_pramod) 's Twitter Profile Photo

Listening to stalwarts can change the way you look at a disease completely ! Sunday morning well spent ! #rheumtwitter Thank you sir Durga Prasanna Misra for such a lucid and evidence based lecture on TAK And thank you Dr. Kavita Krishna for always bringing the best in the field !

Listening to stalwarts can change the way you look at a disease completely ! Sunday morning well spent !  #rheumtwitter
Thank you sir <a href="/DurgaPrasannaM1/">Durga Prasanna Misra</a>  for such a lucid and evidence based lecture on TAK
And thank you <a href="/kavitak1967/">Dr. Kavita Krishna</a> for always bringing the best in the field !
Bhaskar Dasgupta (@profbdasgupta) 's Twitter Profile Photo

Great privilege to talk to the faculty of JIPMER my Alma Mater on standards that MUST underpin care of GCA PMR and Large vessel vasculitis. Any guidelines that suggest less imaging may not be fit for purpose ⁦Polymyalgia+GCA

Great privilege to talk to the faculty of JIPMER my Alma Mater on standards that MUST underpin care of GCA PMR and Large vessel vasculitis. Any guidelines that suggest less imaging may not be fit for purpose ⁦<a href="/PMRGCAuk/">Polymyalgia+GCA</a>⁩
Ritesh Mishra (@riteshkumarmis3) 's Twitter Profile Photo

Thanks to Bhaskar Dasgupta's insightful JIPMER talk! Stratifying the GCA/PMR spectrum-Stop one size fits all, use of HAS-GCA for headache in older patients:the fast-track pathway, watch for LVV signs in PMR are key takeaways. #GCAPMR #MedTwitter #Vasculitis

Thanks to <a href="/profbdasgupta/">Bhaskar Dasgupta</a>'s insightful JIPMER talk! Stratifying the GCA/PMR spectrum-Stop one size fits all, use of HAS-GCA for headache in older patients:the fast-track pathway, watch for LVV signs in PMR are key takeaways. 
#GCAPMR 
#MedTwitter #Vasculitis
JIPMER - Official (@officialjipmer) 's Twitter Profile Photo

On #WorldAnkylosingSpondylitisDay, @JIPMER's Rheumatology Dept held a successful education event with 70+ participants!✅ Early Dx ✅ Physio & DMARDs ✅ Mental health Engaged Q&A & great feedback! Empowered patients = better outcomes. #ASDay2025 #AxSpA #RheumTwitter #JIPMER

On #WorldAnkylosingSpondylitisDay, @JIPMER's Rheumatology Dept held a successful education event with 70+ participants!✅ Early Dx ✅ Physio &amp; DMARDs ✅ Mental health Engaged Q&amp;A &amp; great feedback! Empowered patients = better outcomes. #ASDay2025 #AxSpA #RheumTwitter #JIPMER
TheDaoIndex (@kdao2011) 's Twitter Profile Photo

ICYMI: The 2025 ACR #Lupus Guidelines Summary are published on @acrheum. They address each organ system: hematologic, neuropscyhiatric, SkM, cutaneous, cardiopulmonary, & systemic vasculitis. @acrheum Laurent ARNAUD Dr. John Cush Donald Thomas, MD Mithu Maheswaranathan, MD assets.contentstack.io/v3/assets/blte…

ICYMI: The 2025 ACR #Lupus Guidelines Summary are published on @acrheum. They address each organ system: hematologic, neuropscyhiatric, SkM, cutaneous, cardiopulmonary, &amp; systemic vasculitis. @acrheum <a href="/Lupusreference/">Laurent ARNAUD</a> <a href="/RheumNow/">Dr. John Cush</a> <a href="/lupuscyclopedia/">Donald Thomas, MD</a> <a href="/MithuRheum/">Mithu Maheswaranathan, MD</a>  assets.contentstack.io/v3/assets/blte…
ACR_Journals (@acr_journals) 's Twitter Profile Photo

Editorial on this study in Arthritis & Rheumatology: "Kerschbaumer and colleagues have introduced a new issue to consider in evaluating large multicenter randomized trials, spotlighting the high rates of placebo response, rates that are threatening the ability to detect efficacy

Editorial on this study in Arthritis &amp; Rheumatology:
"Kerschbaumer and colleagues have introduced a new issue to consider in evaluating large multicenter randomized trials, spotlighting the high rates of placebo response, rates that are threatening the ability to detect efficacy